

Ascendiant Capital Markets LLC serves as Sole M&A Advisor on PAVmed, Inc.'s Acquisition of CapNostics, LLC

JUPITER, Florida – October 11, 2021 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the completion of a definitive purchase agreement between PAVmed, Inc. (Nasdaq: PAVM) of New York, New York, and CapNostics, LLC of Concord, North Carolina.

Ascendiant served as the Sole M&A Advisor on the transaction.

CapNostics manufactures EsophaCap®—a U.S. FDA 510(k)-cleared and European CE Mark certified, non-endoscopic esophageal cell collection device which has been used in pre-commercial clinical research of esophageal precancer biomarkers at major academic medical centers.

About PAVmed, Inc.

PAVmed Inc. (Nasdaq: PAVM) is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its major subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer. Its GI Health division also includes the complementary EsoCure™ Esophageal Ablation Device with Caldus™ Technology. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care. Its Minimally Invasive Interventions division markets its CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome. Other divisions include Infusion Therapy and Emerging Innovations. For more information, please visit www.pavmed.com

About Ascendiant Capital Markets LLC

Ascendiant Capital Markets, LLC, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendiant has led or participated in over \$1 billion in financing transactions, and the members of Ascendiant's Investment Banking Team have completed over 300 M&A transactions.

Ascendiant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendiant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 561.427.1727 or bwilhite@ascendiant.com

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.